EcoDrugPlus

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSCGOG00000013678
Gene Symbol: PPP3CA
3 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSCGOG00000011000
Gene Symbol: PTK2
3 Cross references
241 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSCGOG00000014104
Gene Symbol: PTK2B
3 Cross references
196 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSCGOG00000024247
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSCGOG00000010114
Gene Symbol: PTPRB
3 Cross references
201 Possible Orthologues:

Protein-Tyrosine Kinase 6-Like

Ensembl ID : ENSCGOG00000021949
Gene Symbol: LOC115004532
3 Cross references
160 Possible Orthologues:

Proteinase-Activated Receptor 1-Like

Ensembl ID : ENSCGOG00000017879
Gene Symbol: LOC115016995
3 Cross references
265 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSCGOG00000009258
Gene Symbol: LOC115010684
3 Cross references
198 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSCGOG00000001240
Gene Symbol: P2RX3
3 Cross references
200 Possible Orthologues:

Purinergic Receptor P2x 7

Ensembl ID : ENSCGOG00000008280
Gene Symbol: P2RX7
3 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSCGOG00000002166
Gene Symbol: P2RY1
3 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSCGOG00000004496
Gene Symbol: P2RY2
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).